Decision: Favourable

Study Title:

Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn’s Disease

  • NREC Code:

    21-NREC-CT-095

  • Decision:

    Favourable

  • Meeting Date:

    06/10/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Laurence Egan

  • PI Institution:

    University Hospital Galway

  • Sponsor:

    Boehringer Ingelheim

Scroll to Top
Skip to content